Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) EPS (Weighted Average and Diluted) (2016 - 2025)

Dare Bioscience's EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$0.02 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 96.92% year-over-year to -$0.02; the TTM value through Dec 2025 reached -$1.25, down 155.1%, while the annual FY2025 figure was -$1.2, 150.0% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.02 in Q4 2025 per DARE's latest filing, up from -$0.28 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.52 in Q2 2024 to a low of -$1.22 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.3, with a median of -$0.18 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 27199.85% in 2023, then surged 224.59% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.18 in 2021, then fell by 5.56% to -$0.19 in 2022, then crashed by 268.42% to -$0.7 in 2023, then rose by 7.14% to -$0.65 in 2024, then surged by 96.92% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for DARE's EPS (Weighted Average and Diluted) are -$0.02 (Q4 2025), -$0.28 (Q3 2025), and -$0.45 (Q2 2025).